Novartis AG vs Twist Bioscience Corp — how do they compare? Novartis AG trades at $153.53 (market cap $298.18B), while Twist Bioscience Corp trades at $124 (market cap $7.82B). The key difference: Novartis AG is far larger — about 38.1× Twist Bioscience Corp's market cap, and Novartis AG pays a 3.02% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| NVS | TWST | |
|---|---|---|
Market Cap | $298.18B | $7.82B |
Sector | Health | Health |
52-Week High | $168.62 | $124.88 |
52-Week Low | $119.31 | $24.16 |
Enterprise Value | $339.50B | $7.75B |
Dividend Yield | 3.02% | — |
Trailing returns across standard periods
Latest headlines on both assets
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →